drug
Spexotras
Marketedupdated 3mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 3 investigational indications.
all catalysts(43)
approval · 43
May 29, 2013
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 8, 2014
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Aug 13, 2014
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Sep 26, 2014
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Nov 20, 2015
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Feb 24, 2017
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jun 22, 2017
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 9, 2018
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Apr 30, 2018
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
May 4, 2018
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jul 16, 2019
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Oct 6, 2019
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Apr 9, 2020
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jun 23, 2020
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
May 7, 2021
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Dec 3, 2021
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 28, 2022
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 28, 2022
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
May 27, 2022
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jun 22, 2022
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 16, 2023
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 16, 2023
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
May 26, 2023
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Aug 31, 2023
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Feb 27, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Feb 27, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Mar 29, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 29, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Jul 11, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Jul 11, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Oct 1, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Oct 1, 2024
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Jan 24, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Jan 24, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 7, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Mar 7, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 19, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 19, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Apr 7, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Apr 7, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Apr 21, 2025
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 26, 2026
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 26, 2026
approval
$NVS156.24-2.54%
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Trials studying Spexotras
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 16, 2026
25 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (52)
- Feb 28, 2034patentUS 10869869*PED
- Feb 28, 2034patentUS 10869869*PED
- Feb 28, 2034patentUS 10869869*PED
- Aug 30, 2033method-of-use (U-3184)US 10869869
- Aug 30, 2033method-of-use (U-3184)US 10869869
- Aug 30, 2033method-of-use (U-3184)US 10869869
- Jul 28, 2032patentUS 8580304*PED
- Jul 28, 2032patentUS 8580304*PED
- Jul 28, 2032patentUS 8580304*PED
- Jul 28, 2032patentUS 9155706*PED
- Jul 28, 2032patentUS 9155706*PED
- Jul 28, 2032patentUS 9155706*PED
- Jul 28, 2032patentUS 9271941*PED
- Jul 28, 2032patentUS 9271941*PED
- Jul 28, 2032patentUS 9271941*PED
- Jul 28, 2032patentUS 9399021*PED
- Jul 28, 2032patentUS 9399021*PED
- Jul 28, 2032patentUS 9399021*PED
- Jan 28, 2032formulationUS 8580304
- Jan 28, 2032formulationUS 8580304
- Jan 28, 2032formulationUS 8580304
- Jan 28, 2032formulationUS 9155706
- Jan 28, 2032formulationUS 9155706
- Jan 28, 2032formulationUS 9155706
- Jan 28, 2032formulationUS 9271941
- Jan 28, 2032formulationUS 9271941
- Jan 28, 2032formulationUS 9271941
- Jan 28, 2032formulationUS 9399021
- Jan 28, 2032formulationUS 9399021
- Jan 28, 2032formulationUS 9399021
- Apr 15, 2031patentUS 8703781*PED4.6y
- Apr 15, 2031patentUS 8703781*PED4.6y
- Apr 15, 2031patentUS 8703781*PED4.6y
- Apr 15, 2031patentUS 8703781*PED4.6y
- Apr 15, 2031patentUS 8952018*PED4.6y
- Apr 15, 2031patentUS 8952018*PED4.6y
- Apr 15, 2031patentUS 8952018*PED4.6y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030compositionUS 87037814.2y
- Oct 15, 2030method-of-use (U-2020)US 89520184.2y
- Oct 15, 2030method-of-use (U-2020)US 89520184.2y
- Oct 15, 2030method-of-use (U-2020)US 89520184.2y
- Nov 29, 2027patentUS 7378423*PED1.3y
- Nov 29, 2027patentUS 7378423*PED1.3y
- Nov 29, 2027patentUS 7378423*PED1.3y
- Nov 29, 2027patentUS 7378423*PED1.3y
- May 29, 2027compositionUS 7378423280d
- May 29, 2027compositionUS 7378423280d
- May 29, 2027compositionUS 7378423280d
- May 29, 2027compositionUS 7378423280d
FDA exclusivities (16)
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Sep 16, 2030PEDPediatric (6mo bonus)4.1y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Mar 16, 2030ODE-428Orphan Drug (7y)3.6y
- Sep 16, 2026PEDPediatric (6mo bonus)25d
- Sep 16, 2026PEDPediatric (6mo bonus)25d
- Sep 16, 2026PEDPediatric (6mo bonus)25d
- Sep 16, 2026PEDPediatric (6mo bonus)25d
- Mar 16, 2026NPNP
- Mar 16, 2026I-908Indication (3y)
- Mar 16, 2026I-908Indication (3y)
- Mar 16, 2026I-908Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that